Evidence map›Paper›PMID 39365474›Full record

ArticleWiener klinische Wochenschrift2025

S100 as marker for immune effector cell-associated neurotoxicity syndrome.

Axel Schulenburg, Lina Z Rüsing, Armin Bumberger, Margit Mitterbauer, Werner Rabitsch

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Wiener klinische Wochenschrift, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Axel SchulenburgBone Marrow Transplantation Unit, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria. axel.schulenburg@meduniwien.ac.at.ORCID http://orcid.org/0000-0003-2662-0446
Lina Z RüsingBone Marrow Transplantation Unit, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.
Armin BumbergerBone Marrow Transplantation Unit, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.
Margit MitterbauerBone Marrow Transplantation Unit, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.
Werner RabitschBone Marrow Transplantation Unit, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chimeric antigen receptor (CAR)-T cell therapy is a new and successful treatment for otherwise refractory malignancies but despite the growing number of applications, this form of treatment is still associated with significant toxicity. Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) in particular are common and dangerous side effects. This report is about two patients who received CAR‑T cell therapy and subsequently developed ICANS. This was successfully treated. During CAR‑T cell therapy, a blood marker, S100, was monitored daily. It correlated with the occurrence and progression of ICANS.

Indexed as

Cytokine Release SyndromeImmunotherapy, AdoptiveNeurotoxicity SyndromesS100 ProteinsAgedBiomarkersHumansMaleReceptors, Chimeric AntigenBiomarkerscell-associated neurotoxicityReceptors, Chimeric AntigenS100 ProteinsChimeric antigen receptor (CAR)-T cell therapyMarkerNeurologySide effectsToxicity

Identifiers

PMID39365474
PMCPMC12370851

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.